Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 17/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.80 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.80 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.80 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.80 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.80 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.80 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.80 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14672155 | 0.90 | HDAC6 (0.85) | HDAC4HDAC6HDAC1HDAC7HDAC8 | |
| SCHEMBL14752370 | 0.89 | HDAC4 (0.62) | HDAC4HDAC6HDAC1HDAC7HDAC8 | |
| SCHEMBL6976560 | 0.89 | HDAC4 (1.00) | HDAC4HDAC6HDAC1HDAC7HDAC8 | |
| SCHEMBL29349803 | 0.89 | HDAC4 (1.00) | HDAC4HDAC6HDAC1HDAC7HDAC8 | |
| SCHEMBL6975604 | 0.89 | HDAC4 (0.80) | HDAC4HDAC6HDAC1HDAC7HDAC8 | |
| SCHEMBL2225588 | 0.88 | HDAC4 (0.81) | HDAC4HDAC6HDAC1HDAC7HDAC8 | |
| SCHEMBL2225274 | 0.87 | HDAC4 (0.84) | HDAC4HDAC6HDAC1HDAC7HDAC8 | |
| SCHEMBL6977317 | 0.84 | HDAC6 (0.91) | HDAC4HDAC6HDAC1HDAC7HDAC8 | |
| SCHEMBL6976584 | 0.84 | HDAC4 (0.91) | HDAC4HDAC6HDAC1HDAC7HDAC8 | |
| SCHEMBL6973005 | 0.84 | HDAC6 (0.90) | HDAC4HDAC6HDAC1HDAC7HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | claimed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | claimed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | claimed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | HDAC4 1441/4885HDAC6 1474/4885HDAC1 640/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | HDAC4 1441/4885HDAC6 1474/4885HDAC1 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.